A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Decompensated Heart Failure

In brief

To evaluate the overall safety and efficacy of TRV027 when administered in addition to standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients hospitalized with Acute Decompensated Heart Failure (ADHF).

Key facts

Study ID

NCT01966601

Run by

Trevena Inc.

People needed

620

Starts

2013-12-01

Expected to finish

2016-09-01

Last updated by the study team

2018-07-26

Who can join

Age: 21 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women aged ≥21 years and ≤ 85 years 1a.Women of non-child-bearing potential
• Able to provide written informed consent
• Pre-existing diagnosis of heart failure and at least 30 days treatment with daily oral loop diuretics
• Systolic blood pressure ≥105 mmHg and ≤ 160 mmHg within 30 minutes of randomization
• Ventricular rate ≤125 bpm. Patients with rate-controlled persistent or permanent atrial fibrillation (aFib) at screening are permitted.
• Presence of ADHF defined by:
• BNP > 400 pg/mL or NT-proBNP > 1600 pg/mL
• For patients with BMI >30 kg/m2: BNP > 200 pg/mL or NT-proBNP > 800 pg/mL
• For patients with rate-controlled persistent or permanent aFib: BNP > 600 pg/mL or NT-proBNP > 2400 pg/mL
• Congestion on chest radiograph (CXR)
• AND at least two (2) of the following:
• Rales by chest auscultation
• Edema ≥ +1 on a 0-3 + scale, indicating indentation of skin with mild digital pressure that requires 10 or more seconds to resolve in any dependent area including extremities or sacral region.
• Elevated jugular venous pressure (≥8 cm H2O)
• Receipt of a IV loop diuretic at a minimum dose 40 mg furosemide (or equivalent loop diuretic) for the treatment of dyspnea due to ADHF at least 1 hour prior to anticipated randomization and the initiation of study medication
• Patient report of dyspnea at rest or upon minimal exertion during screening at least one hour after administration of IV loop diuretic

You may not qualify if…

• Women who are pregnant or breast-feeding
• Clinical presentation:
• Suspected ACS based on clinical judgment
• Coronary revascularization in the 3 months prior to screening or planned during current admission.
• Temperature >38.5oC
• Clinically significant anemia
• Serum sodium >145 mEq/L (145 mmol/L)
• Current or planned ultrafiltration, paracentesis, hemofiltration or dialysis at time of screening
• Any mechanical ventilation
• CPAP/BiPAP discontinued less than 1 hour prior to randomization
• History of LVAD or IABP within the last year
• Intravenous radiographic contrast agent within 72 hours prior to screening or presence of acute contrast induced nephropathy at the time of screening
• Presence of clinically significant arrhythmia
• Uncertainty of ability to complete follow up
• Medications:
• nitroprusside or nesiritide
• Intravenous nitrates
• use of inotropes
• Use of ARBs within 7 days of prior to randomization
• Use of any investigational medication within 30 days
• clinically significant hypersensitivity or allergy to, or intolerance of, angiotensin receptor blockers
• Medical history:
• Major surgery within 8 weeks prior to screening
• Stroke within 3 months prior to screening
• eGFR (sMDRD) <20 mL/min/1.73m2 or >75 mL/min/1.73m2 between presentation and randomization

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States
• Tennessee Center for Clinical Trials — Tullahoma, Tennessee, United States
• Michael E Debakey VA Medical Center — Houston, Texas, United States
• Research Site — Buenos Aires, Argentina
• Research Site — Coronel Suárez, Argentina
• Research Site — Corrientes, Argentina
• Research Site — Córdoba, Argentina
• Research Site — La Plata, Argentina
• Research Site — Morón, Argentina
• Research Site — Quilmes, Argentina
• Research Site — Rosario, Argentina
• Research Site — San Martin, Argentina
• Research Site — San Miguel de Tucumán, Argentina
• Research Site — Santa Fe, Argentina
• Research Site — Dimitrovgrad, Bulgaria
• Research Site — Kazanlak, Bulgaria
• Research Site — Pazardzhik, Bulgaria
• Research Site — Pleven, Bulgaria
• Research Site — Smolyan, Bulgaria
• Research Sites — Sofia, Bulgaria
• Research Site — Sofia, Bulgaria
• Research Site — Edmonton, Alberta, Canada
• Research Site — Ottawa, Ontario, Canada
• Research Site — Brno, Czechia
• Wayne State University — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.